Vitrolife’s Q4 delivers a high 56.9% gross margins despite a quarter with an unfavorable Technology and Consumable mix. Another positive is that the US Genetic Services headwind is gradually fading, and we expect the next, more significant improvement to be delivered after Q1 in 2024. Our updated view is a base case valuation of SEK 245 (235), a Bull Case of SEK 400 (375), and a Bear Case of SEK 100 (95).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitrolife Q4 - Strong margins and gradually improving Genetic Services

© Modular Finance, source Nordic Press Releases